Skip to content

Study · Randomized controlled trial · n = 60 · 1996

5 results

Depot goserelin and danazol pre-treatment before rollerball endometrial ablation for menorrhagia.

Fraser IS, Healy DL, Torode H, Song JY, Mamers P, Wilde F

Obstetrics and gynecology1 Apr 1996Cited by 21 (Europe PMC)

PMID8602306 (opens in a new tab)DOI10.1016/0029-7844(95)00475-0 (opens in a new tab)PepBankPUB-08602306
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with menorrhagia after ablation, complete amenorrhea occurred in 74% after goserelin versus 62% after danazol at 6 months.

    In plain wordsAfter ablation, complete amenorrhea occurred in 74% after goserelin versus 62% after danazol.

    Peptide
    Goserelin
    Outcome
    Direction not reportedComplete amenorrhea
    Study

    n = 60

    Comparator
    Danazol before ablation
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.6 mg monthly · subcutaneous implant · 2 monthsAs given in this study (human).

    Measurements

    Complete amenorrhea by 6 months after ablation
    74%
    goserelin
    Complete amenorrhea by 6 months after ablation
    62%
    danazol

    Source sentences

    Summary
    Measured menstrual blood loss decreased dramatically after ablation, with 74% of goserelin users and 62% of danazol users achieving complete amenorrhea by the end of the 6-month follow-up period.
    2 context sentences
    Summary · context
    We performed an open, randomized study of women with clinically convincing histories of menorrhagia.
    Summary · context
    Two treatment groups of equal size (goserelin acetate, 3.6 mg subcutaneous implant given monthly, n = 30; and danazol, 200 mg two times per day, n = 30) were treated for 2 months before undergoing endometrial ablation
  2. 02HumanRandomized controlled trialEfficacy outcome

    After ablation for menorrhagia, blood loss fell from 94.8 mL to 1.1 and 1.0 mL after goserelin versus 97.9 to 15.0 and 7.4 mL after danazol at 3 and 6 months, respectively.

    In plain wordsAfter ablation, blood loss decreased from baseline with both goserelin and danazol.

    Peptide
    Goserelin
    Outcome
    DecreaseMeasured blood loss
    Study

    n = 60

    Comparator
    Baseline measured blood loss
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.6 mg monthly · subcutaneous implant · 2 monthsAs given in this study (human).

    Measurements

    Mean measured blood loss at baseline
    94.8 mL
    goserelin
    Mean measured blood loss at 3 months
    1.1 mL
    goserelin
    Mean measured blood loss at 6 months
    1 mL
    goserelin
    Mean measured blood loss at baseline
    97.9 mL
    danazol
    Mean measured blood loss at 3 months
    15 mL
    danazol
    Mean measured blood loss at 6 months
    7.4 mL
    danazol

    Source sentences

    Summary
    Mean measured blood loss decreased from 94.8 to 1.1 mL at 3 months and 1.0 mL at 6 months after goserelin, and 97.9 to 15.0 mL and 7.4 mL after danazol.
    2 context sentences
    Summary · context
    We performed an open, randomized study of women with clinically convincing histories of menorrhagia.
    Summary · context
    Two treatment groups of equal size (goserelin acetate, 3.6 mg subcutaneous implant given monthly, n = 30; and danazol, 200 mg two times per day, n = 30) were treated for 2 months before undergoing endometrial ablation
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with menorrhagia, endometrial thickness was below 2 mm in all goserelin users and most danazol users.

    In plain wordsEndometrial thickness was below 2 mm in all goserelin users and most danazol users.

    Peptide
    Goserelin
    Outcome
    Not applicableEndometrial thickness
    Study

    n = 60

    Comparator
    Danazol before ablation
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.6 mg monthly · subcutaneous implant · 2 monthsAs given in this study (human).

    Measurements

    Endometrial thickness
    < 2 mm
    all goserelin users

    Source sentences

    Summary
    Endometrium was less than 2 mm thick in all goserelin and most danazol users.
    2 context sentences
    Summary · context
    We performed an open, randomized study of women with clinically convincing histories of menorrhagia.
    Summary · context
    Two treatment groups of equal size (goserelin acetate, 3.6 mg subcutaneous implant given monthly, n = 30; and danazol, 200 mg two times per day, n = 30) were treated for 2 months before undergoing endometrial ablation
  4. 04HumanRandomized controlled trialEfficacy outcome

    Among women without complete amenorrhea after ablation, occasional moderate or heavy bleeding was less likely after goserelin than danazol.

    In plain wordsAmong women without amenorrhea, moderate or heavy bleeding was less likely after goserelin than danazol.

    Peptide
    Goserelin
    Outcome
    DecreaseModerate or heavy bleeding
    Study

    n: not reported in source

    Comparator
    Danazol before ablation
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.6 mg monthly · subcutaneous implant · 2 monthsAs given in this study (human).

    Source sentences

    Summary
    Among women who did not achieve complete amenorrhea, those in the danazol group were more likely to experience occasional episodes of moderate or heavy bleeding.
    2 context sentences
    Summary · context
    We performed an open, randomized study of women with clinically convincing histories of menorrhagia.
    Summary · context
    Two treatment groups of equal size (goserelin acetate, 3.6 mg subcutaneous implant given monthly, n = 30; and danazol, 200 mg two times per day, n = 30) were treated for 2 months before undergoing endometrial ablation
  5. 05HumanNon-randomized trialSafety outcome

    In women with menorrhagia, goserelin side effects followed the expected pattern.

    In plain wordsGoserelin side effects followed the expected pattern in women with menorrhagia.

    Peptide
    Goserelin
    Outcome
    Not applicableSide effects
    Study

    n: not reported in source

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    3.6 mg monthly · subcutaneous implant · 2 monthsAs given in this study (human).

    Source sentences

    Summary
    Side effects of goserelin and danazol therapy were all within the expected pattern for these drugs.
    2 context sentences
    Summary · context
    We performed an open, randomized study of women with clinically convincing histories of menorrhagia.
    Summary · context
    Two treatment groups of equal size (goserelin acetate, 3.6 mg subcutaneous implant given monthly, n = 30; and danazol, 200 mg two times per day, n = 30) were treated for 2 months before undergoing endometrial ablation

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.